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Background: The casual and severity distribution of allergic rhinitis (AR) in Hungary is unknown.
The aim of this survey was to evaluate symptom perception, disease severity, concomitant asthma frequency and
the impact of AR on everyday life activities in a cross-sectional, multicenter study in Hungary under the supervision
of Hungarian Respiratory Society.
Methods: Data were recorded by 933 AR patients (65.93% women) and their treating specialists. The perceptions of
patients regarding the symptoms (nasal, ocular and others) of AR and its severity, together with its impact on
everyday life were assessed. Physicians recorded data regarding the diagnosis and severity of AR, and comorbidities.
Results: 52.5% of patients suffered from seasonal AR, 35.1% from perennial AR. A large proportion of patients had
moderate to severe disease (MS-AR) (57.34%), persistent disease (98.0%) and concomitant asthma (53.32% in the
mild, 57.52% in the MS-AR group). MS-AR was more frequent among women. Despite the treatment used, in MS-AR
the proportions of patients reporting moderate to severe rhinorrhoea, nasal obstruction, ocular itching/redness,
watering, itchy throat and sneezing were as high as 52.0%, 54.0%, 33.8%, 26.5%, 44.0% and 31.2%, respectively.
Overall, there was a poor agreement between disease severity reported by patients and specialists. The adherence
to oral antihistamines and intranasal corticosteroids was found to be between 50 and 65%; mostly depending on
the dosage form.
Conclusions: AR remains a significant health problem in Hungary because of the burden of symptoms, high rate of
concomitant asthma and the significant proportion of MS-AR affecting general well being.
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The incidence and prevalence of allergic rhinitis (AR)
has increased worldwide over the past decades. Pres-
ently, AR is the most common allergic respiratory dis-
order, affecting about 10-30% of the general population
worldwide, depending on the area and on the age of
patients. About 19% of the general population in Europe,
while 8.8% to 16% in the United States of America suf-
fers from mild or moderate-severe AR [1,2]. The disease
is associated with limited or severe incapacitating symp-
toms that can affect health-related quality of life, leisure
activities, and work productivity even though it responds* Correspondence: tamasi@pulm.sote.hu
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reproduction in any medium, provided the oreffectively to treatment in most cases [3-5]. AR is fre-
quently associated with comorbidities such as asthma,
sinusitis, otitis media or bridge warp and the coexistence
of asthma and allergic rhinitis is characterized by a more
severe clinical presentation [6,7]. Between 20% and 50%
of patients with AR have asthma, and 30% to 90% of
patients with asthma have concomitant AR [8,9]. The se-
verity of AR may be mild or moderate to severe based
on its interference with normal sleeping, daily activities,
work and school performance [10].
Although the prevalence of AR is increasing in Hungary
according to some national epidemiological data [11],
there are no data either on its casual and severity dis-
tribution or on the rate of its association with asthma.
The aim of the present study was to identify the percep-
tion of symptoms and the impact of AR on everyday lifetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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concomitant asthma frequency and causative allergens in
a cross-sectional, multicenter survey in Hungary.
Methods
The present multicenter cross-sectional study was
initiated and supervised by the Hungarian Respiratory
Society and was conducted with Hungarian National
Ethical Board approval. All the counties in Hungary
were represented with sample sizes proportional to re-
spective general population sizes. The perceptions of
patients and physicians regarding the symptoms of AR
and its severity and impact on general well being and
everyday life were assessed. All the attending doctors
were specialists, including allergy specialists, ear, nose
and throat doctors and respiratory physicians, and they
enrolled the AR patients consecutively on the occasion
of patients’ regular visits. AR was diagnosed by the phy-
sicians, and adult patients were targeted. Physicians
recorded data relating to patient characteristics, diagno-
sis, AR severity, common triggers, comorbidities, current
and past drug treatments and smoking history.
Data were recorded for 933 patients suffering from AR
between June 1st, 2009 and October 1st, 2009. It must be
noted that a patient number above 1,000 was targeted;
however 74 surveys were either not completely filled out
or were not filled out at all, so these surveys were not
used in the data analysis. 65.93% women (N=615) and
34.07% men (N=318) were enrolled (Table 1). Mean,
standard deviation and median age of patients were
41.93, 14.67 and 41, respectively; ages were between 12
and 79. The 25th and 75th percentiles of the age distribu-
tion were 30 and 54 years (as some physicians participat-
ing in the study attended also children, few patients
below the age of 18 years were also enrolled to maintain
the consecutiveness of the enrollment). Diagnostic skin
prick tests to confirm AR had been performed on
97.18% of patients at least since the diagnosis. Allergen
specific IgE antibody tests were carried out in 22.86% ofTable 1 General characteristics of the enrolled patients
with allergic rhinitis (AR) (persistent disease defined as
symptoms experienced on > 4 days/week and for > 4
consecutive weeks)
Total number of patients 933
Sex, % (n) Male: 34.07% (318)
Female: 65.93% (615)
Age, yrs (mean ± SD) 41.93 ± 14.67
Seasonal/perennial/mixed or
unknown etiology (%)
52.5 / 35.1 /12.4
Mild AR (%) 42.66
Moderate to severe AR (%) 57.34
Persistent AR (%) 98.0patients. 14.6% of the patients were smokers, 19.42% ex-
smokers, while 65.93% non-smokers. Patients’ character-
istics are summarized in Table 1. Physicians completed a
patient record form for each patient, and patients were
invited to complete a self-completed form.
Data regarding the presence and severity of AR symp-
toms as well as the impact of AR on everyday life activ-
ities were reported by the patients using a questionnaire
which was developed by the authors based strictly on Al-
lergic Rhinitis and its Impact on Asthma (ARIA) guide-
line [10] for this study. Patients recorded information on
disease history, symptoms and their severity, the impact
of AR on normal activities and treatment adherence.
Furthermore, potential factors having an impact on the
level of AR control were evaluated by a supplementary
questionnaire developed by our research group. Among
the typical AR associated symptoms nasal, ocular and
others were taken into consideration. As nasal abnor-
malities: rhinorrhoea and nasal obstruction; as ocular
complaints: ocular itching/redness and watering; as
other symptoms: sneezing and itchy throat were rated
using a score system of 0–3 for each symptom, where
0 = no symptoms, 1 = mild symptoms, 2 = moderate
symptoms and 3 = severe symptoms. Thus, the total of
nasal, ocular and other scores could have been between 0
and 6, where the higher was the total score the most se-
vere was the symptom. Besides the physicians’ evaluation
of the severity of AR (whether it was mild or moderate to
severe according to ARIA guideline) [10], the disease se-
verity was also recorded based on patients’ opinion.
Patients’ records on the presence of abnormal sleep,
impairment of daily activities (sport, leisure), impaired
work and school productivity or troublesome symp-
toms caused by AR were also analyzed (as AR severity
determinants according to ARIA guideline). Adherence
to medications prescribed for AR was recorded by
patients. Missed doses of various treatment forms in
the last month were rated as three times or more,
once/twice, or never. The optimal adherence was con-
sidered if no doses were missed in the last month be-
fore the study. The informed consent was obtained
from all participants.
Statistics
In the present study Student’s-t test was used and a p
value of < 0.05 was considered significant. To assess any
association between AR severity and sex we used the
chi-square (χ2) method.
Results
Patients’ characteristics
According to the physicians’ assessment, 42.66% of
patients had mild and 57.34% moderate or severe dis-
ease. 52.5% of patients suffered from seasonal, while
Table 2 Severity of nasal (rhinorrhoea and nasal
obstruction), ocular (ocular itching/redness, tearing) and
other (sneezing and itchy throat) symptoms were rated
using a 0–3 categorical scale, where 0 = no symptoms,
1 = mild symptoms, 2 = moderate symptoms and 3 =
severe symptoms
Mild AR Moderate-severe AR
Total score (mean ± SD)
Total nasal 0.88 ± 0.83 3.02 ± 1.51
Total ocular 0.49 ± 0.77 2.06 ± 1.64
Total AR 1.68 ± 1.48 6.11 ± 2.95
In case of mild AR and moderate-severe AR patients the total nasal and total oral
scores (between 0 and 6) for nasal and ocular symptoms are given as mean ± SD.
Furthermore, the sum of total scores for nasal, ocular and other symptoms is
given as total AR symptom score (between 0 and 18) (mean ± SD). All p < 0.05.
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types of AR were identified (for 8.4% of patients there
were no data). Aeroallergens most frequently involved in
seasonal atopic sensitization were ragweed, mugwort,
and birch, while the most common cause of perennial
disease was house dust mite. Overall, 98.0% of the
patients surveyed had persistent disease (defined as
symptoms experienced on > 4 days/week and for > 4
consecutive weeks).
Physicians reported on the cause of visits. Most
patients (49.5%) were consulting for repeat prescriptions,
30.9% for routine follow up, and 14.1% because of wor-
sening symptoms (5.5% of patients did not answer the
question regarding the cause of doctor visit). Comparing
the groups of mild AR and moderate-severe AR, the
causes of physician visits were markedly different. In
case of mild AR only 1% of patients were consulting due
to symptom worsening and 34% for routine follow up.
On the contrary, regarding moderate-severe AR patients
22.4% visited their specialist because of disease deterior-
ation and only 22% for routine follow up.
Severity of AR was gender related. While among mild
AR patients only 61.23% were women, in case of
moderate-severe AR 69.23% of the patients were woman,
pointing on higher prevalence of moderate-severe AR
among women (χ2< 0.05). The mean ages were not sig-
nificantly different between the two severity groups
(41.17±14.87 vs. 42.46±14.52 years, mild vs. moderate/
severe, respectively; p > 0.05). The frequency of food
cross-allergy was found to be higher among moderate to
severe AR patients (23%) than in the subcategory of mild
AR (16%). AR had been diagnosed 5.2 years before in
mild AR, and 7.0 years before for moderate-severe
patients at the visit.
Comparing the assessment of disease severity of physi-
cians and patients - using two-sided t-test with a signifi-
cance level of 0.05 - it was found that patients rated
their disease differently from the physicians. Among
patients having mild disease according to the physi-
cians’ assessment, 16.28% rated their disease as mode-
rate/severe. On the other hand, among patients estimated
moderate/severe by physicians, 38.04% rated their disease
as mild.
Symptomatology
Table 2 shows the total scores for nasal (rhinorrhoea
and nasal obstruction), ocular (ocular itching/redness,
watering) and other (sneezing and itchy throat) symp-
toms and symptom perception according to disease se-
verity (based on physicians records). In the moderate to
severe AR group total scores regarding all symptoms
were rated higher than in mild AR patients (all p < 0.05).
Despite the treatment used, in moderate to severe AR
group the proportion of patients reporting moderate tosevere rhinorrhoea and nasal obstruction was as high as
52.0% and 54.0%, respectively (Table 3). Furthermore
the proportion of subjects with marked ocular itching/
redness, watering, itchy throat and sneezing was 33.8%,
26.5%, 44% and 31.2%, respectively in this group.
Impact on sleep and daily activities
In mild AR the disease impact on normal everyday activ-
ities and sleep was negligible. On the contrary, for ap-
proximately 30.7% of moderate to severe AR patients,
the symptoms of AR had a significant impact on sleep
patterns or caused sleep disturbances, despite the pre-
scribed AR medications. The majority of the moderate
to severe AR patients reported that their symptoms had
an impact on daily activities, 24.0% of them reported
reduced work/school performance, while 20.2% noticed
poor concentration ability. Summarizing the impact of
AR on daily activities, 66.0% of moderate to severe AR
patients reported mild difficulties, while 8.5% of them
had remarkable difficulties because of AR (Figure 1).
Comorbidities
AR itself is not a life-threatening condition, however, it
disposes to some comorbidities, such as sinusitis, otitis
media, bridge warp etc., and it is a strong risk factor for
the development of asthma. The prevalence of asthma
was found to be 53.32% in the mild, while 57.52% in the
moderate to severe AR group. Based on otolaryngologic
examination which was performed in 67.63% of enrolled
moderate to severe AR patients, the prevalence of other
comorbidities was determined, too; (data are shown in
Figure 2).
Treatment adherence
The patients used oral antihistamines and intranasal
corticosteroids according to the physicians’ prescrip-
tions. All the mild AR patients were prescribed oral
antihistamines (cetirizine, levocetirizine, fexofenadine,
Table 3 Frequency (%) of various symptoms in the mild and moderate/severe AR groups
Type and severity of symptoms Severity of AR
Mild AR (%) Moderate/Severe AR (%)
Nasal symptoms Nasal obstruction No 55.5 14.6
Mild 44.5 31.3
Moderate 0.0 41.8
Severe 0.0 12.2
Rhinorrhoea No 56.1 12.2
Mild 43.9 35.8
Moderate 0.0 41.0
Severe 0.0 11.0
Ocular symptoms Ocular itching/redness No 71.3 26.1
Mild 28.7 40.0
Moderate 0.0 27.4
Severe 0.0 6.4
Watering No 80.2 38.3
Mild 19.5 35.2
Moderate 0.0 21.5
Severe 0.3 5.0
Other symptoms Sneezing No 57.6 13.3
Mild 42.4 42.7
Moderate 0.0 33.8
Severe 0.0 10.2
Itchy throat No 68.8 30.7
Mild 30.9 38.1
Moderate 0.0 26.1
Severe 0.3 5.1
Szilasi et al. Multidisciplinary Respiratory Medicine 2012, 7:49 Page 4 of 6
http://www.mrmjournal.com/content/7/1/49loratadine or desloratadine) and patients with moder-
ate to severe disease were on both oral antihistamine
and intranasal steroid (momethasone, budesonide,
fluticasone-propionate or -furoate) therapy in most
cases. The optimal adherence regarding antihistamine
tablets was reported to be as low as 64.32% for mild0
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Figure 1 Proportion of patients reporting sleep disturbances, everyda
performance due to moderate to severe allergic rhinitis in Hungary.and 60.19% for moderate-severe AR patients, while
regarding intranasal corticosteroids 50.15% and 50.22%
for mild and severe AR group, respectively. Evaluating
the possible causes of non-adherence the following
were identified: 39.68% of mild AR and 31.49% of
moderate-severe AR patients were without symptoms,Work/School 
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Figure 2 Proportion of moderate to severe allergic rhinitis
patients with various concomitant diseases in Hungary.
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values for nasal corticosteroids were 88.66% and
64.29%. The second most frequent reason of non-
adherence with oral treatment was forgetting to take
it: this was recorded in 40.48% and 35.91% of mild
and moderate/severe AR patients, respectively. Of note,
regarding intranasal steroids, this reason was rarely
indicated. Side effects were the causes of non-
adherence only in 2-4%.
Discussion
This cross-sectional, multicenter survey was the first to
evaluate the severity, impact on everyday life activities,
symptom perception, and concomitant asthma frequency
in allergic rhinitis patients in all counties of Hungary.
Conducted among 933 patients with AR presenting to
their specialist, the study found that AR was mostly con-
firmed with diagnostic tests in Hungary. A marked pro-
portion of patients had moderate or severe disease
(57.34%), persistent symptoms (98.0%) and comorbidities
such as asthma (53.32% in the mild, while 57.52% in the
moderate to severe AR). Underrepresentation of patients
with intermittent disease might be the consequence of
over-the-counter freely available antihistamine tablets
available for intermittent AR patients for 4 weeks with-
out medical prescription.
As reflected in this and other surveys, AR imposes a
substantial burden on patients regarding everyday life
limitations and work performance [12,13]. Nearly 60% of
AR patients had moderate to severe disease, and these
patients – although treated – showed marked nasal and
ocular allergic rhinitis symptoms and hence suffered
from sleep- and concentration disturbances, limitations
on everyday life activities, and poor work/school prod-
uctivity. Majority of moderate to severe patients in this
survey considered that they had remarkable difficulties
because of AR. However, patients with mild AR did not
show limitations regarding any aspects of everyday life.
Our results confirm higher rate of seasonal AR and
are similar to those of AILA study (Allergies in LatinAmerica), revealing that 62% of Latin American AR
patients are seasonally affected, with the remaining 38%
suffering year-long symptoms [14]. In the study of
Navarro et al. [9] 46% of cases were intermittent, 54%
persistent, 43% mild, and 57% moderate-severe. Pereira
et al. [15], whose study included 3225 subjects attending
the allergy clinics, found that 36% had intermittent rhin-
itis, 64% persistent rhinitis, 59% mild rhinitis, and 41%
moderate-severe rhinitis. Bachert et al. [16] assessed the
data of 554 subjects recruited from the general popula-
tion with rhinitis symptoms. They found that 59% had
intermittent rhinitis, 41% persistent rhinitis, 25% mild
rhinitis, and 75% moderate-persistent rhinitis. Bousquet
et al. reported that 46% of 3,052 subjects had intermit-
tent rhinitis, 54% persistent rhinitis, 19% mild rhinitis,
and 81% moderate-severe disease [17]. Consistent with
findings from previous surveys, it can be concluded that
the prevalence of moderate to severe AR is higher
among women than among men [1]. Likewise previous
data, also this survey found high symptom burden
among moderate to severe-, and a very good symptom
control in mild AR patients who presented to their phys-
ician [13,16]. The most frequent patient-reported symp-
toms were: nasal congestion and obstruction as well as
rhinorrhoea and ocular symptoms; in agreement with
the results of Asia-Pacific Survey of Katelaris et al. [18].
Overall, there was only a poor correlation between the
AR severity evaluated by physicians and that based on
patients’ opinion. In good agreement with previous
results of Canonica et al. [5] it can be concluded that
physicians underrate the severity of AR in many cases.
The underestimation of the severity may partially lead to
adherence problems. Non-adherence to the prescribed
therapeutic regimen is a worldwide problem. Reviews
about various diseases conducted across countries are
consistent in estimating non-compliance between 30
and 50% [19]. However, it is clear that adequate manage-
ment of AR, including the patient’s adherence, is essen-
tial to achieve optimal therapeutic outcome. In our
survey the compliance with tablet-taking and nasal spray
use was found to be between 50 and 65%; mostly de-
pending on the dosage form (higher for tablet-taking)
and being fast independent from the severity of AR.
Several studies have confirmed the importance of rhin-
itis symptoms in the future development of asthma [20].
The severity of rhinitis may also affect the development
of asthma. In the present study the prevalence of asthma
was found to be 53.32% in the mild, while 57.52% in the
moderate-severe AR group. Other authors have found
disparate results according to the population studied.
Marogna et al., in an epidemiologic study carried out
in 832 subjects with intermittent rhinitis, found that
11.6% developed asthma when AR was mild and 22.2%
when the condition was moderate-severe, whereas in
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developed asthma when AR was mild and moderate-
severe, respectively [3].
This is the only multicenter study ever conducted in
Hungary to describe the symptoms, impact on everyday
life and concomitant asthma frequency of AR; however
as a real-life investigation it has many limitations. The
bias on symptom severity caused by a possible not
proper AR diagnosis or treatment non-adherence cannot
be excluded in some cases. There were 74 surveys which
were not included in the analysis due to missing data.
Furthermore, some local and oral antihistamines, nasal
decongestants may be purchased over-the-counter in
pharmacies, therefore their use is completely unknown
in this survey.
Conclusion
In conclusion, this survey, enrolling 933 patients with AR
presenting to their specialist and lead by the Hungarian
Respiratory Society, found that a significant proportion
of patients have moderate or severe disease, persistent
symptoms and comorbidities such as asthma in Hungary.
A more severe disease was shown to be more frequent
among women. Furthermore, our results highlighted
the poor symptom control of patients who presented
with moderate or severe and persistent disease.
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